BioCentriq, the New Jersey Innovation Institute’s cell and gene therapy development and manufacturing center, on March 23 announced it partnered with Kytopen, a Cambridge-based startup spun out of the Massachusetts Institute of Technology (MIT).
“Our mission at BioCentriq is to work with innovative industry partners like Kytopen to advance the production and manufacturing of cell and gene therapies, making them accessible and affordable for the patients who so desperately need them,” said Haro Hartounian, and SVP, general manager, BioCentriq. “This partnership aligns perfectly with that mission.”
Kytopen’s proprietary Flowfect technology is a flexible, complete technology solution for non-viral cell engineering that integrates the discovery, development, and manufacturing of cell and gene therapeutics. The platform speeds therapies from the clinic to commercial use by enabling cell engineering without compromising functionality or viability. Kytopen’s technology reduces risk and provides maximum control and flexibility to drive higher yields, faster approvals, and better outcomes for curative cellular disease treatment.
“The Flowfect platform is a transformative solution that eliminates the complexity of gene delivery for cell engineering and links discovery, development and manufacturing in one flexible scalable solution,” stated Paulo Garcia, CEO and co-founder of Kytopen. “Our goal is to enable simple and efficient non-viral manufacturing of cell therapies in days versus weeks to help patients; our partnership with BioCentriq accelerates that goal.”
“Our Flowfect technology utilizes a novel combination of electrical energy and continuous fluid flow to engineer cells,” said Bethany Grant, head of research and development at Kytopen. “Our ability to engineer billions of cells in minutes with minimal disruption unlocks new opportunities to enable curative therapies in autologous or allogeneic therapeutic applications.”
In the initial phase of the collaboration, the Kytopen and BioCentriq teams will demonstrate the impact to both autologous and allogeneic cell therapies by integrating this novel transfection technology with other steps in the manufacturing process.
BioCentriq has a manufacturing facility in Newark and a pilot plant in South Brunswick.
1 of 2
1 article remaining
Advance your business edge with news from NJBIZ. Register now for more article access.